Clinical trial
A Phase IIb, Open-Label, Randomized Controlled Dose Ranging Multi-Center Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Exposure-Response Relationship of Different Doses of BTZ-043 in Combination With Bedaquiline and Delamanid in Adult Subjects With Newly Diagnosed, Uncomplicated, Drug-sensitive Pulmonary Tuberculosis
NCT05926466 is registered in ClinicalTrials.gov with Michael Hoelscher as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIb, Open-Label, Randomized Controlled Dose Ranging Multi-Center Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Exposure-Response Relationship of Different Doses of BTZ-043 in Combination With Bedaquiline and Delamanid in Adult Subjects With Newly Diagnosed, Uncomplicated, Drug-sensitive Pulmonary Tuberculosis
- Lead sponsor
- Michael Hoelscher
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 21, 2023
- Completion date
- December 27, 2024
- Enrollment
- 92 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
other specified pulmonary tuberculosis, tuberculosis, pulmonary